Mineralys Therapeutics, Inc. (MLYS)
Automate Your Wheel Strategy on MLYS
With Tiblio's Option Bot, you can configure your own wheel strategy including MLYS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLYS
- Rev/Share 0.0
- Book/Share 6.4246
- PB 2.4375
- Debt/Equity 0.0
- CurrentRatio 26.4833
- ROIC -0.5899
- MktCap 1020645198.0
- FreeCF/Share -3.6246
- PFCF -5.2966
- PE -4.4164
- Debt/Assets 0.0
- DivYield 0
- ROE -0.7115
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend
Published: May 01, 2025 by: 24/7 Wall Street
Sentiment: Negative
Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.
Read More
Insiders Make Huge Purchases of These 4 Biotech Stocks
Published: March 26, 2025 by: 24/7 Wall Street
Sentiment: Neutral
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Read More
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
Read More
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
Published: March 10, 2025 by: Benzinga
Sentiment: Positive
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday.
Read More
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Khadkar - LifeSci Capital Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call.
Read More
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
Read More
About Mineralys Therapeutics, Inc. (MLYS)
- IPO Date 2023-02-10
- Website https://mineralystx.com
- Industry Biotechnology
- CEO Mr. Jon Congleton
- Employees 51